DS
MRNA icon

David Shaw’s Moderna MRNA Stock Holding History

David Shaw’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Sell
1,447,500
-820,300
-36% -$42.4M 0.05% 442
2026
Q1 		$115M Buy
2,267,800
+401,200
+21% +$18.7M 0.07% 327
2025
Q4 		$55M Buy
1,866,600
+490,100
+36% +$13.3M 0.03% 663
2025
Q3 		$35.6M Buy
1,376,500
+339,700
+33% +$9.48M 0.02% 832
2025
Q2 		$28.6M Buy
1,036,800
+802,500
+343% +$21.1M 0.02% 832
2025
Q1 		$6.64M Sell
234,300
-433,300
-65% -$15.4M 0.01% 1692
2024
Q4 		$27.8M Sell
667,600
-10,000
-1% -$478K 0.02% 845
2024
Q3 		$45.3M Sell
677,600
-101,500
-13% -$9.32M 0.04% 556
2024
Q2 		$92.5M Sell
779,100
-4,400
-0.6% -$557K 0.09% 274
2024
Q1 		$83.5M Buy
783,500
+87,100
+13% +$8.78M 0.07% 311
2023
Q4 		$69.3M Buy
696,400
+64,100
+10% +$5.39M 0.06% 375
2023
Q3 		$65.3M Buy
632,300
+248,700
+65% +$27.7M 0.07% 341
2023
Q2 		$46.6M Sell
383,600
-25,900
-6% -$3.46M 0.05% 464
2023
Q1 		$62.9M Buy
409,500
+146,700
+56% +$24.2M 0.07% 353
2022
Q4 		$47.2M Buy
262,800
+146,500
+126% +$24M 0.05% 456
2022
Q3 		$13.8M Sell
116,300
-208,900
-64% -$31.7M 0.02% 1105
2022
Q2 		$46.5M Buy
325,200
+188,900
+139% +$27M 0.05% 431
2022
Q1 		$23.5M Sell
136,300
-75,100
-36% -$12.6M 0.02% 922
2021
Q4 		$53.7M Sell
211,400
-50,500
-19% -$14.8M 0.04% 507
2021
Q3 		$101M Sell
261,900
-100,800
-28% -$37.2M 0.09% 253
2021
Q2 		$85.2M Sell
362,700
-131,200
-27% -$23.4M 0.07% 318
2021
Q1 		$64.7M Buy
493,900
+450,300
+1,033% +$65.3M 0.06% 378
2020
Q4 		$4.55M Sell
43,600
-21,900
-33% -$2.22M ﹤0.01% 1949
2020
Q3 		$4.63M Buy
65,500
+50,400
+334% +$3.51M ﹤0.01% 1759
2020
Q2 		$970K Buy
+15,100
New +$827K ﹤0.01% 2963

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

David Shaw's MRNA Position: Q2 2026 in Review

David Shaw reduced its Moderna (MRNA) stake by 96% in Q2 2026, selling an estimated $33.2M and leaving 24,951 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

David Shaw first reported a position in MRNA in Q2 2019 and has held it in 27 quarters since. The position peaked at $393M in Q2 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • David Shaw held 24,951 shares of Moderna worth $1.75M as of Q2 2026.
  • David Shaw sold 641,581 Moderna shares in Q2 2026, an estimated $33.2M.
  • Moderna made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3317 holding.
  • David Shaw first reported a position in Moderna in Q2 2019 and has held it in 27 quarters since.
  • David Shaw's Moderna position peaked at $393M in Q2 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.